

1 **A NOVEL ELECTROCARDIOGRAPHIC PREDICTION MODEL FOR DIAGNOSING**
2 **CONCEALED BRUGADA SYNDROME: RESULTS FROM A CLINICAL TRIAL OF**
3 **AJMALINE PROVOCATION IN HEALTHY SUBJECTS**
4

5 Bode Ensam¹ MBChB, Chiara Scrocco¹ MD, David Johnson¹ PhD, Yanushi D.
6 Wijeyeratne¹ PhD, Rachel Bastiaenen¹ PhD, Belinda Gray^{1,3}, Chris Miles¹ PhD, Yael
7 Ben-Haim¹ MD, Stathis Papatheodorou¹ MD, Sanjay Sharma¹ MD, Michael
8 Papadakis¹ MD, Brian Devine² MSc, Peter W. Macfarlane² DSc, Elijah R. Behr¹ MD.
9

10 **Affiliations:**

11 ¹Cardiology Section and Cardiovascular Clinical Academic Group, St. George's
12 University Hospitals NHS Foundation Trust, London, UK and Institute of Molecular
13 and Clinical Sciences, St George's University of London, London, UK.

14 ²Electrocardiology Group, School of Health and Wellbeing, University of Glasgow.

15 ³Faculty of Medicine and Health, University of Sydney, NSW, Australia
16

17 **Funding:**

18 This work is supported by The Robert Lancaster Memorial Fund sponsored by
19 McColl's, Cardiac Risk in the Young UK, and the British Heart Foundation
20 (PG/19/58/34581).

21 BG is the recipient of a NHMRC Early Career Fellowship (#1122330).
22

23 **Disclosures:**

24 The authors have no relevant conflicts of interest to disclose.
25

26 **Acknowledgements:**

27 Dr Velislav Batchvarov MD (posthumous), Cardiology Clinical Academic Group, St.
28 George's University Hospitals NHS Foundation Trust, London, UK and Institute of
29 Molecular and Clinical Sciences, St George's University of London, London, UK,
30

31 **CORRESPONDING AUTHOR:**
32

33 Professor Elijah R. Behr
34 St. George's, University of London,
35 St. George's University Hospitals NHS Foundation Trust
36 Cranmer Terrace
37 Tooting
38 London
39 SW17 0RE
40 ebehr@sgul.ac.uk
41 +442087252994
42 Twitter @BehrElijah
43

44 **Word Count:** 3127 (text only)

45 **Figures:** 4

46 **Tables:** 7

47 **Supplementary Figures:** 2

48 **Supplementary Tables:** 2
49
50

51 **Background**

52

53 Clinical, electrocardiographic, and genomic factors have been associated with the
54 drug-induced type 1 Brugada pattern (DI-T1BP), in response to sodium channel
55 blocker provocation (SCBP). However, prior analyses have been concerned with
56 prediction of the DI-T1BP rather than the validity of the diagnosis of concealed
57 Brugada syndrome (BrS). We sought to analyse and compare the ECG response to
58 SCBP with ajmaline in a cohort of healthy controls (HC) and a definite BrS group
59 (Def-BrS) to develop a diagnostic score.

60

61 **Methods**

62

63 Healthy controls (HC) were systematically recruited as part of a clinical trial.
64 Following comprehensive cardiovascular screening, eligible subjects underwent
65 SCBP with ajmaline. We identified a Def-BrS cohort, defined as a DI-T1BP and a
66 Shanghai Score (SS) ≥ 3.5 , from consecutive patients with suspected BrS
67 undergoing SCBP with ajmaline using the identical protocol. Def-BrS and HC were
68 divided equally into discovery and validation cohorts. Digital ECG acquisition
69 facilitated automated measurement of ECG parameters. A multivariable analysis
70 compared ECG parameters between the HC and Def-BrS cohorts. A logistic
71 regression analysis identified ECG characteristics that accurately predicted the
72 diagnosis of Def-BrS. This model was then assessed in the validation cohort.

73

74 **Results**

75

76 Two-hundred-and-forty-eight volunteers completed an online questionnaire, 103
77 accepted an invitation to undergo further screening and 100 were recruited into the
78 HC group. Three HCs developed a DI-T1BP. From 1241 patients undergoing SCBP,
79 166 were Def-BrS. There were no demographic differences between the HC
80 discovery and validation groups or between the Def-BrS discovery and validation
81 groups. Following multivariable logistic regression analysis, QRS duration, mean
82 anterior lead ST segment amplitude at baseline, maximum change in QRS duration,
83 anterior ST segment amplitude and QRS area after SCBP, were independently
84 associated with Def-BrS. The combined model was an excellent discriminator for
85 Def-BrS, with an area under the curve of 0.95 [95% confidence interval (CI) = 0.912
86 – 0.989], $P < 0.001$ in the discovery groups and 0.97 [95% CI = 0.948 – 0.998],
87 $P < 0.001$ in the validation groups.

88

89 **Conclusion**

90

91 The yield of the DI-T1BP in HCs is 3%. However, there are distinct ECG parameters
92 at baseline and in response to SCBP that favour a definite diagnosis of BrS. These
93 observations permit the quantifiable refinement of the ECG diagnosis of concealed
94 BrS, avoiding the pitfalls of relying upon the DI-T1BP alone.

95 **INTRODUCTION**

96

97 The yield of the drug-induced type 1 Brugada pattern (DI-T1BP), across a spectrum
98 of clinical and experimental scenarios has been described previously ⁽¹⁻⁴⁾.
99 Additionally, the clinical, electrocardiographic, and genomic factors associated with
100 the development of the DI-T1BP in response to sodium channel blocker provocation
101 (SCBP) have been investigated ⁽⁵⁾. However, these prior analyses have been
102 concerned with the prediction of the DI-T1BP rather than the strength or validity of
103 the diagnosis of Brugada syndrome (BrS).

104

105 In response to a perceived higher than expected yield of the DI-T1BP in the clinical
106 setting and an uncertainty regarding false positives, an international consensus
107 document downgraded the response to SCBP from diagnostic to probabilistic. With
108 the proposed Shanghai scoring system (SS), an isolated DI-T1BP is insufficient to
109 make a diagnosis of “definite Brugada Syndrome ⁽⁶⁾.” The scoring system is,
110 however, based largely on expert opinion.

111

112 Furthermore, the response to SCBP is not binary, rather, several temporal ECG
113 changes may be observed, and it is postulated to exacerbate a pre-existent impaired
114 right ventricular outflow tract (RVOT) conduction reserve to unveil the DI-T1BP ⁽⁷⁾.
115 The significance of baseline and dynamic ECG traits in affected and unaffected
116 subjects is poorly understood but may provide a quantitative element to the drug-
117 induced BrS phenotype.

118

119 We sought to analyse and compare the ECG response to SCBP with ajmaline in a
120 cohort of healthy subjects, Healthy Controls (HC), and clinical patients with a DI-
121 T1BP, thus proposing a quantitative ECG model for the diagnosis of definite
122 concealed BrS.

123

124 **METHODS**

125

126 **Recruitment**

127 **Healthy Controls (HC):** Subjects responded to online advertisements seeking
128 healthy volunteers as part of an interventional clinical trial, (*ClinicalTrials.gov*
129 *Identifier: NCT02933437, EudraCT Number 2016-004277-41*), with ethical approval
130 from London - Southeast Research Ethics Committee, (*16/LO/2173*).

131

132 A comprehensive online medical questionnaire was used to identify eligible subjects
133 (supplementary data I). Those fulfilling the initial inclusion criteria (supplementary
134 data II), were invited to attend for further eligibility testing with a focused
135 cardiovascular examination, baseline resting 12 lead and high right precordial lead
136 (HRPL) ECG with additional leads placed in the V1 and V2 position in the 2nd and
137 3rd intercostal spaces, (supplementary data III). A baseline transthoracic
138 echocardiogram (TTE) was also performed. Those with any ECG or structural
139 abnormality outside of normal physiological range were excluded (supplementary
140 data II). Participants were compensated for their time.

141

142 **Clinical cohort:** From an existing clinical cohort of consecutive patients investigated
143 at our centre for suspected BrS between 2010 – 2022, we identified those with DI-

144 T1BP and a definite diagnosis of BrS according to a $SS \geq 3.5$ (Def-BrS group).
145 Patients within the clinical cohort were evaluated in a dedicated clinic by experienced
146 clinicians following international recommendations and provided informed consent,
147 (NHS Research Ethics Committee reference 10/H0803/121). The indication for
148 SCBP included unexplained cardiac arrest (UCA) in the subject, or BrS, sudden
149 arrhythmic death (SADS) or UCA in a first-degree relative.

150

151 **Study cohort:** The HC and Def-BrS group were equally divided into discovery (HC-
152 Dis and Def-BrS-Dis) and validation groups (HC-Val and Def-BrS-Val) groups
153 respectively.

154

155 **Sodium channel blocker provocation:** All subjects underwent SCBP with ajmaline
156 according to a standardised protocol of 1mg/kg (maximum dose 100mg)
157 administered intravenously over 5 minutes. The SCBP test was terminated early
158 once the DI-T1BP was observed, if QRS prolongation increased $\geq 150\%$ of the
159 baseline measurement, or if a ventricular arrhythmia was encountered. The DI-T1BP
160 was defined as J point elevation $\geq 0.2\text{mV}$ with coved ST elevation in a right precordial
161 chest lead.

162

163 **ECG acquisition and analysis:** SCBP was undertaken using HRPL placement. A
164 continuous ECG was acquired digitally using a CardioSoft resting digital recorder
165 (GE Healthcare, Milwaukee, WI, USA) with a sampling rate of 500 samples/sec and
166 $4.88\mu\text{V}$ amplitude resolution. The low pass filter was set at 150 Hz. From the
167 continuous ECG recording a 10-second HRPL ECG was obtained at 1-minute
168 intervals from the beginning of drug administration for a minimum of 10 minutes.

169 ECGs were stored in XML format and imported onto a secure ECG server for
170 analysis. Relevant and novel ECG parameters were measured using bespoke
171 automated ECG analysis software developed in partnership with the
172 Electrocardiology Group, School of Health and Wellbeing, University of Glasgow.
173 Beats with excessive noise were excluded from analysis and a combination of lead-
174 specific and global ECG parameters were analysed using single beats and a derived
175 representative beat respectively.

176

177 Quantitative ECG parameters were measured at baseline (time 00:00 of ajmaline
178 administration) and at peak drug effect, (denoted as maximum QRS duration (ms)
179 from a representative beat), which were expressed as delta values (Δ = peak –
180 baseline). See Table 1.0 and supplementary material IV for ECG parameters.

181

182 **Shanghai Score:** The clinical, familial, and genetic components of the SS were
183 applied according to the recommended scoring system⁽⁶⁾. However, to investigate
184 the significance of a baseline type 2/3 Brugada pattern (T2/3BP) as a categorical
185 covariate in the prediction of Def-BrS, an ECG score of 2.0 was given to all who
186 developed the T1BP irrespective of the presence of T2/3BP on the baseline ECG. If
187 a spontaneous or fever induced T1BP was observed at any point during follow up
188 the ECG score was adjusted accordingly.

189

190 **STATISTICAL ANALYSIS**

191

192 **General Statistical Methods:** Data were analysed with IBM ® SPSS ® Statistics
193 version 29. Categorical variables are presented as frequencies (percentages) and

194 were compared using the χ^2 or Fishers exact test where appropriate. For continuous
195 variables, the Kolmogorov–Smirnov test was used to test the distribution of data. The
196 Mann-Whitney test was performed to compare differences between non-normally
197 distributed continuous variables, which are reported as median [1st quartile – 3rd
198 quartile]. Normally distributed continuous variables were analysed using an
199 independent sample T-test and are reported as mean \pm standard deviation (SD). A
200 value of $P < 0.05$ was considered significant in all cases. A paired intragroup analysis
201 of ECG characteristics was undertaken and is provided in supplementary data V.

202

203 **Variable Filters and Model Development:** Candidate variables from the univariate
204 analysis between the HC-Dis and Def-BrS-Dis groups with a statistical significance
205 of $P \leq 0.05$ were included in a multivariate binomial logistic regression model.
206 Following this, variables that were independently associated with the diagnosis of
207 Def-BrS (odds ratio (OR) ≥ 1.0 and $P \leq 0.05$), were included in the predictive model.
208 To assess for overfitting, we used the Akaike Information Criterion (AIC) and
209 Bayesian Information Criterion (BIC), and we assessed the performance of the
210 proposed model using the validation groups.

211

212 **RESULTS**

213

214 *Demographic and clinical characteristics*

215 Two hundred-and-forty-eight (248) prospective healthy subjects completed the online
216 medical questionnaire, 68 applicants were excluded at this stage due to prior cardiac
217 symptoms or suspicious family history. One-hundred-and-eighty were deemed
218 suitable and were invited for further eligibility testing with 103 attending. Two

219 subjects were excluded because of baseline ECG abnormalities and one subject
220 was excluded due to a borderline TTE abnormality. We did not observe a
221 spontaneous T1BP or T2/3BP in any of the subjects undergoing screening. The final
222 cohort of 100 healthy controls underwent SCBP (Figure 1.0).

223

224 From a clinical cohort of 1241 consecutive patients undergoing AP, 372 (30%) had a
225 DI-T1BP. One hundred-and-sixty-six of these patients, 45% (166/372), had a SS of
226 ≥ 3.5 and comprised the Def-BrS cohort (Figure 1.0).

227

228 Table 2.0 highlights the demographic and clinical characteristics of the overall HC
229 and Def-BrS cohorts. Of note the HC cohort were significantly younger in age than
230 the Def-BrS cohort, median age 24.53 years (Q1 21.78 – Q3 29.04) vs. 42.50 (Q1
231 28.00 – Q3 59.21), $P < 0.01$. Within the Def-BrS cohort, 31% (51/166) were BrS
232 probands and 33% (55/166) had a history of syncope prior to evaluation. During
233 follow-up 12% (20/166) were found to have a spontaneous T1BP on one or more
234 occasion and 4% (6/166) had spontaneous T1BP associated with fever. The
235 presence of a T1BP in a 1st or 2nd degree relative was the most frequent indication
236 for SCBP in the Def-BrS cohort, 60% (99/166). In the combined Def-BrS group, 10%
237 (17/166) had a baseline type 2/3 Brugada pattern (T2/3BP). However, no HC's had a
238 baseline T2/3BP ($P = 0.02$). A pathogenic variant in the *SCN5A* gene was identified
239 in 19% (31/166) Def-BrS subjects. The mean time to peak drug effect was
240 significantly earlier in the Def-BrS group compared to HC group 05min18secs
241 (± 2 min05secs) vs. 05min59secs (± 01 min20secs), $P = 0.01$. Mean final SS in the Def-
242 BrS group was 4.3 (± 0.75) vs. 0.06 (± 0.34) in the HC group.

243

244 *Electrocardiographic Characteristics and Analyses*

245 Overall, 3 subjects in the HC group developed the DI-T1BP during SCBP, 3/100
246 (3%) (Figure 2.0). At baseline, all 3 subjects had a partial right bundle branch block
247 pattern (RBBB) with a sharp r' but without resting J-point elevation in at least one
248 HRPL. In 2 of these 3 subjects, the DI-T1BP was observed in a single high-right
249 precordial chest lead (HRPL) only, whilst in the remaining subject (subject 3), the DI-
250 T1BP was seen in the 4th and 3rd intercostal spaces (ICS) and was borderline
251 (<0.2mV J-point elevation) in the 2nd ICS.

252

253 The 100 HC and 166 Def-BrS subjects were equally and randomly divided into the
254 respective discovery and validation groups. There were no significant demographic
255 or clinical differences between the Def-BrS-Dis and Def-BrS-Val cohorts (Table 3.0).
256 Similarly, there were no demographic differences between the HC-Dis and HC-Val
257 cohorts (Table 4.0).

258

259 The independent sample univariable analysis of baseline ECG characteristics
260 demonstrating a statistically significant difference between the discovery groups is
261 highlighted in Table 5.0. Similarly, Table 6.0 highlights the univariable analysis of
262 statistically significant Δ ECG characteristics.

263

264 Following a combined multivariable analysis of baseline and Δ ECG characteristics
265 significantly in favour of Def-BrS (OR >1.0 and $P \leq 0.05$) in the discovery cohort,
266 anterior ST amplitude (Adj. OR. 1.027 [95% Confidence Interval 1.005 – 1.046], $P =$
267 0.014) and QRS duration (Adj. OR. 1.096 [1.010 – 1.190], $P = 0.028$) were
268 independent baseline predictors of Def-BrS. The Δ Anterior ST amplitude (Adj.

269 OR.1.027 [1.012 – 1.043]), $P < 0.001$, Δ QRS area (Adj. OR. 1.008 [1.004 – 1.013],
270 $P < 0.001$ and Δ QRS duration (Adj. OR. 1.127 [1.050 – 1.209], $P < 0.001$) were SCBP
271 associated ECG characteristics independently predictive of Def-BrS (Table 7.0).

272

273 The adjusted odds ratios per 10-unit increment for the final ECG characteristics in
274 the Def-BrS diagnostic ECG model are highlighted in Figure 3.0. The final ECG
275 model was 92.8% sensitive and 90.0% specific, with an overall accuracy of 91.7%
276 for Def-BrS and predicted the correct group membership in the 2 HC in the discovery
277 cohort with a DI-T1BP. With an area under the receiver operator curve (AUROC) of
278 0.95 [0.912 – 0.989], $P < 0.001$, the combined model was an outstanding
279 discriminator for the diagnosis of Def-BrS. The optimal predictive probability from the
280 derived ECG model was 0.617 (with 0.00= healthy control and 1.00= definite BrS
281 syndrome) which corresponded with a sensitivity of 92.8% and specificity 96.0%
282 (Figure 4.0).

283

284 In the validation group, a similar performance was observed with an AUROC = 0.97
285 [0.948 – 0.998], $P < 0.001$. Similar levels of sensitivity and specificity were observed
286 97.6% and 90.0% respectively with an overall accuracy of 94.7%. The optimal
287 predictive probability was 0.502 which corresponded to a sensitivity of 97.6% and
288 specificity of 99%. Again, the model predicted the correct group membership in the 1
289 HC in the validation group with a DI-T1BP

290

291 The AIC of the intercept only was 178.103 and 85.636 with the final model
292 suggesting a good fit. Similarly, the BIC of the intercept only was 180.993 and
293 102.978 with the final model. The R^2 for the overall model was 0.732.

294

295

296 **DISCUSSION**

297

298 We report the first systematic assessment of diagnostic SCBP with ajmaline in a
299 large cohort of asymptomatic healthy Caucasian subjects without i) a family history
300 of sudden or unexplained death, ii) ECG or structural abnormalities. We identified
301 that the DI-T1BP may be observed in 3% of healthy individuals. In addition, baseline
302 anterior ST segment amplitude, baseline global QRS duration, Δ precordial QRS
303 area, Δ anterior ST amplitude and Δ global QRS duration were independently
304 associated with a diagnosis of *definite* concealed BrS. In combination, these ECG
305 characteristics were able to accurately distinguish between the healthy and those
306 with Def-BrS with a high level of specificity and sensitivity. Therefore, these
307 quantitative characteristics can enhance diagnostic certainty for BrS.

308

309 *Comparison to previously reported yields*

310 In clinical cohorts, the yield of the DI-T1BP with ajmaline is variable; in relatives of
311 SADS victims a yield of 14-15% has been observed ^(1, 8). However, in survivors of
312 UCA, a yield of 20-22% has been reported ^(8, 9). Hasdemir *et al* observed a yield of
313 the DI-T1BP with ajmaline of 27.1% in cohort of Turkish patients with a diagnosis of
314 atrioventricular nodal re-entrant tachycardia (AVNRT) but without a baseline ECG
315 suspicious for BrS ⁽⁴⁾. Of note, in those with AVNRT and a DI-T1BP who underwent
316 genetic testing, a variant in a gene related to sodium channel current was identified
317 in 76.5%. However, pathogenicity of these variants was uncertain and baseline
318 conduction intervals (PR, HV and QRS) were normal, rendering these variants

319 unlikely to be clinically relevant. Interestingly, in the study by Hasdemir *et al*, a DI-
320 T1BP was observed in 4.5% of the control subjects who were unrelated and free
321 from any atrial and ventricular arrhythmia. In contrast to our study, neither family
322 history nor a history of syncope were used to screen controls. The false positive rate
323 of SCBP with ajmaline is therefore likely to be between 3.0-4.5% in individuals
324 without cardiovascular symptoms. However, the false positive rate may be higher in
325 those with a history of palpitations suggestive of AVNRT, and clinicians must be
326 aware of this prior to SCBP.

327

328 *Baseline ECG characteristics*

329 A T2/3BP was observed at baseline in 10% of patients with Def-BrS was not seen in
330 any of the HCs, and whilst the odds ratio in the multivariable logistic regression
331 analysis was exponential it was not a statistically significant independent predictor of
332 the diagnosis of Def-BrS in the discovery cohort (OR 1×10^9 , P=0.99). The true
333 significance of a baseline T2/3BP is therefore out of the scope of this study and must
334 be assessed in a larger cohort of clinical patients, including those with low and
335 intermediate diagnostic Shanghai scores.

336

337 In the high lead configuration right ventricular conduction delay or an incomplete
338 right bundle branch pattern can be observed in healthy subjects ⁽¹⁰⁾. Several ECG
339 features have been proposed to aid in the differentiation between a benign r' and a
340 T2/3BP at baseline(11-14), including an assessment of the β angle, which in clinical
341 practice might be challenging to measure. In the combined predictive ECG model,
342 we observed that baseline ST elevation in the precordial leads and QRS duration
343 were independent predictors of the diagnosis of definite Brugada syndrome, with an

344 adjusted OR per 10 μ V of 10.26 (95% CI 10.07 – 10.46), P= 0.007 and 10.76 (95%
345 CI 10.18 -11.37), P= 0.010. These parameters can be measured routinely with a
346 consistent degree of reproducibility in clinical practice.

347

348 *Ajmaline Provoked ECG characteristics*

349 The change in global QRS duration with ajmaline was significantly greater in the Def-
350 BrS-Dis group compared to the HC-Dis group. However, Δ PR interval and Δ P wave
351 duration were significantly greater in the healthy controls. In our study, as with most
352 SCBP protocols, intravenous administration stopped once the DI-T1BP was
353 observed. As a result, the mean actual dose given in the Def-BrS-Dis cohort was
354 78% of the target dose, while the mean actual dose given in the HC-Dis subjects
355 was 100% of the target dose (P<0.01). This might suggest that mechanistically, the
356 observed differences in the Δ PR interval and Δ P wave duration may be dose
357 dependent, whilst the effects on QRS duration and S wave duration in lead II are
358 disease dependent.

359

360 SCBP resulted in a significant increase in ST segment amplitude in the anterior
361 leads in the Def-BrS-Dis group compared to the HC-Dis group. The mean baseline
362 anterior ST amplitude in the Def-BrS-Dis group was 73.87 μ V (\pm 65.87), and at peak
363 drug effect was 208.86 μ V, above the threshold required for a DI-T1BP (>0.2mV).
364 This would suggest that in a proportion of the Def-BrS-Dis group, the DI-T1BP was
365 observed prior to peak drug effect, which in the Def-BrS-Dis group was 04m59s
366 (\pm 02m19s). This is suggestive of a lesser capacity of the RVOT in Def-BrS to
367 withstand the insult of SCBP and therefore less RVOT conduction reserve ⁽⁷⁾.

368 However, the numbers of HCs with a DI-T1BP were too small to conder this a
369 reliable co-variate.

370

371 *Predictive ECG model*

372 In a combined model, the baseline and Δ ECG characteristics that were
373 independently associated with the Def-BrS group (Figure 3.0) predicted group
374 membership with a high level of specificity and sensitivity in the discovery cohort,
375 AUC 0.95, $P < 0.01$. The optimal cut-off value for Def-BrS had 92.8% sensitivity and
376 96.0% specificity. In the validation cohort a similarly high level of accuracy was
377 observed. These findings suggest that a quantitative refinement on the ECG score
378 will enhance the diagnostic power of ajmaline provocation from the binary
379 assessment that currently exists, enabling the identification of those with a firm
380 diagnosis even in the absence of clinical or genetic characteristics that were not
381 incorporated in this study.

382

383 While an external validation of the predictive model in a similar clinical cohort of
384 patients with a DI-T1BP and $SS \geq 3.5$ is desirable, an assessment of the model's
385 performance in a cohort of patients with a DI-T1BP with low or intermediate
386 diagnostic certainty is necessary to determine whether a diagnosis could be
387 "*upgraded*" or "*downgraded*" based on the quantitative ECG score. Finally, an
388 assessment of the association between the ECG model and clinical variables, such
389 as family history, symptoms and genetic information may determine whether these
390 findings can become a 'gold standard' for the diagnosis of concealed BrS.

391

392 *Clinical impact of this study*

393 For the first time in a large cohort of systematically screened Caucasian ‘super-
394 healthy’ subjects, we have determined that a DI-T1BP can be observed in 3%. In
395 clinical practice, clinicians will be guided by this observation to better inform their
396 patients when considering whether to undertake SCBP with ajmaline. The ECG traits
397 in favour of the diagnosis of definite BrS are readily measurable but the accuracy is
398 greatly enhanced by the ability to acquire the ECG digitally and perform a
399 subsequent automated analysis. This should be considered the ideal method for
400 ECG acquisition when performing SCBP.

401

402 *Limitations*

403 Our study used ajmaline, but whether these findings can be extrapolated to other
404 sodium channel blockers is uncertain and should be addressed using a comparative
405 and collaborative approach. Eighty six percent (86%) of the discovery cohort in the
406 study were Caucasian and thus whether the model can be applied to other
407 ethnicities is also uncertain.


408

409 **CONCLUSIONS**

410

411 By leveraging a novel clinical trial of ajmaline in the healthy, we have identified
412 disease-specific ECG changes that are present at baseline and with SCBP that may
413 enhance the diagnostic certainty of a DI-T1BP, and thus lay the groundwork for a
414 gold standard for the diagnosis of concealed Brugada syndrome. We also
415 demonstrated that changes in healthy subjects are observed with ajmaline, including
416 the development of a DI-T1BP in 3%, that may indicate physiological variation in
417 RVOT conduction reserve that is likely to be more impaired in true BrS.

418 **FIGURES AND TABLES**



419

420

421 **Figure 1.0 Cohort recruitment flow diagram.**


422 A – Healthy controls, B – Clinical cohort.

423 SCBP = Sodium Channel Provocation, HC = healthy controls, Def-BrS = definite

424 Brugada syndrome, Def-BrS-Dis = definite Brugada syndrome discovery, Def-BrS-


425 Val = definite Brugada syndrome validation, HC-Dis = healthy control discovery

426 group, HC-Val = healthy control validation group.




427 **Figure 2.0 ECGs for the three healthy controls subjects in which the DI-T1BP**
428 **was observed during ajmaline provocation.**

429



430 **Figure 3.0 Forrest Plot of final ECG characteristics and corresponding**
 431 **adjusted odds ratios per 10unit increment in value. [§]Net area.**

432



433

434

435 **Figure 4.0 ROC curve for the Def-BrS predictive ECG discovery model.**

436 **AUC=Area under the curve.**

437

Lead Measures	Abbreviation	Units
Global Representative Beat Data		
QRS Duration	gQRSDur	ms
T wave Duration	gTDur	ms
PR Interval	gPR	ms
QT Interval	gQT	ms
P wave Duration	gPDur	ms
+Precordial Lead Data		
QRS Duration	QRS_Dur	ms
T peak to T end interval	Tpe_Int	ms
T wave Duration	T_Dur	ms
Anterior ST amplitude	antSTJ_Amp	μV
§QRS Area	QRS_Area	mV/ms
§T wave area	TW_Area	mV/ms
§QRST Area (QRS onset to T wave termination)	QRST_Area	mV/ms
§ST-J point to Tpeak Area (QRS termination to T wave peak)	STj-Tpeak_Area	mV/ms
§Tpeak to Tend Area (T wave peak to T wave termination)	Tpe_Tend_Area	mV/ms
Additional Lead Data		
S wave duration in lead I	S_Dur	ms
S wave amplitude in lead I	S_Amp	μV
+ Precordial lead data = sum of precordial leads / no. precordial leads § Net area ms = milliseconds, μV = microvolts, mV/ms = millivolts per millisecond		

438

439 **Table 1.0 ECG parameters – abbreviations and units of measure**

	HC N = 100	Def-BrS N = 166	P value
Demographics			
Median Age (years) (Q1 - Q3)	24.53 (21.78 – 29.04)	42.50 (28.00 – 59.21)	<0.01
Male Gender	52 (52%)	72 (43%)	0.14
Caucasian Ethnicity	100 (100%)	133 (80%)	<0.01
BrS Proband	-	51 (31%)	<0.01
Syncope	-	55 (33%)	
Baseline T2/3 Brugada pattern	0 (0%)	17 (10%)	0.02
Ajmaline Indication			
Healthy Control	100 (100%)	0 (0%)	-
SADS/UCA relative	-	39 (24%)	
T1BP in a relative	-	99 (60%)	
UCA survivor	-	11 (7%)	
Family History Score			
0	100 (100%)	30 (18%)	-
0.5	-	12 (7%)	
1	-	17 (10%)	
2	-	107 (65%)	
Mean (SD)	0	1.44 (0.81)	
Clinical History Score			
0	100 (100%)	109 (66%)	-
0.5	-	2 (1%)	
1	-	28 (17%)	
2	-	10 (6%)	
3	-	17 (10%)	
Mean (SD)	0	0.60 (0.98)	
ECG Score			
0	97 (97%)	0 (0%)	-
2	3 (3%)	140 (84%)	
3	-	6 (4%)	
3.5	-	20 (12%)	
Mean (SD)	0.06 (0.34)	2.22 (0.51)	
Genetic Score			
0.5	0 (0%)	31 (19%)	-
Mean (SD)	0	0.09 (0.20)	
Ajmaline Provocation			
Pre - ajmaline SS (SD)	0	2.1 (0.80)	<0.01
Final SS (SD)	0.06 (0.34)	4.3 (0.75)	<0.01
Time to Peak Drug Effect (SD)	5m59s (1m20s)	5m18s (2m05s)	0.01
Final dose:Target dose	1.00 (0.00)	0.78 (0.22)	<0.01

440

441 **Table 2.0 Overall cohort demographic and clinical characteristics. HC=Healthy**

442 **Controls. Def-BrS=Definite Brugada Syndrome**

	Def-BrS-Dis N = 83	Def-BrS-Val N = 83	P value
	Demographics		
Median Age (years)	42.5	42.49	0.51
Male Gender	37 (45%)	34 (41.%)	0.64
Caucasian Ethnicity	64 (77%)	69 (83%)	0.33
BrS Proband	24 (29%)	27 (33%)	0.61
Syncope	27 (33%)	28 (34%)	1.00
Baseline T2/3 Brugada pattern	9 (11%)	8 (10%)	0.89
	Ajmaline Indication		
SADS/UCA relative	20 (24%)	19 (23%)	0.82
T1BP in a relative	50 (60%)	49 (59%)	
UCA survivor	4 (5%)	7 (8%)	
	Family History Score		
0	15 (18%)	14 (17%)	0.93
0.5	7 (8%)	5 (6%)	
1	8 (10%)	9 (11%)	
2	53 (64%)	54 (66%)	
Mean (SD)	1.42 (0.82)	1.46 (0.80)	0.74
	Clinical History Score		
0	54 (65%)	55 (66%)	0.10
0.5	1 (1%)	1 (1%)	
1	11 (13%)	17 (21%)	
2	9 (11%)	1 (1%)	
3	8 (10%)	9 (11%)	
Mean (SD)	64 (1.02)	0.56 (0.96)	0.58
	ECG Score		
0	0 (0%)	0 (0%)	0.47
2	69 (83%)	71 (86%)	
3	2 (2%)	4 (5%)	
3.5	12 (15%)	8 (10%)	
Mean (SD)	2.24 (0.54)	2.19 (0.48)	0.55
	Genetic Score		
0.5	16 (19%)	15 (18%)	0.84
Mean (SD)	0.10 (0.20)	0.10 (0.19)	0.84
	Ajmaline Provocation		
Pre - ajmaline SS (SD)	2.16 (0.81)	2.09 (0.75)	0.59
Final SS (SD)	4.40 (0.85)	4.30 (0.63)	0.33
Time to Peak Drug Effect (SD)	04m59s (02:19)	05m05s (01:22)	0.08
Final dose:Target dose (SD)	0.77 (0.23)	0.79 (0.21)	0.65

443

444 **Table 3.0 Comparison between Discovery and Validation Def-BrS cohorts.**

445

	HC-Dis N=50	HC-Val N=50	P value
Median Age in years (Q1-Q3)	22.99 (22.91 - 30.38)	23.26 (20.86 - 26.79)	0.03
Mean age in years (SD)	27.85 (7.45)	25.83 (8.46)	0.21
Male Gender N (%)	26 (52%)	26 (52%)	0.58
Weight in Kg (SD)	74.98 (13.30)	75.49 (11.52)	0.84
Time to peak effect (mm:ss) (SD)	05:51 (01:28)	06:08 (01:10)	0.30
Drug-induced Type 1 Brugada Pattern	4% (2/50)	2% (1/50)	1.00

446

447 **Table 4.0 Comparison between Discovery and Validation HC cohorts. Def-BrS-**

448 **Dis= Definite Brugada Syndrome discovery group.**

	Def-BrS-Dis		HC-Dis		P Value	95% Confidence Interval of the Difference
	N=83 Mean		N=50 Mean			
QRS duration in ms (SD)	99.49	(19.53)	90.56	(9.66)	<0.01	3.08 - 14.79
T wave duration in ms (SD)	192.94	(33.73)	206.44	(25.76)	0.02	-24.48 - -2.53
PR interval in ms (SD)	169.18	(27.22)	151.48	(20.14)	<0.01	8.91 - 26.49
QT interval in ms (SD)	390.39	(32.38)	404.28	(29.37)	0.01	-24.97 - -2.81
P wave duration in ms (SD)	113.57	(15.83)	103.00	(9.89)	<0.01	5.64 - 15.49
S wave duration II in ms (SD)	27.45	(20.19)	18.40	(14.98)	<0.01	2.52 - 15.57
S wave amplitude I in μV (SD)	-129.16	(157.76)	-191.62	(174.73)	0.04	4.27 - 120.65
Precordial lead QRS duration in ms (SD)	94.00	(18.15)	85.87	(9.09)	<0.01	2.68 - 13.59
Anterior lead ST Amplitude in μV (SD)	73.87	(65.87)	44.43	(32.34)	<0.01	9.70 - 49.18
Precordial lead T wave duration in ms (SD)	159.72	(34.77)	171.40	(27.76)	0.05	-23.13 - -0.23
§Precordial lead QRS Area in mV/ms (SD)	-283.15	(339.23)	-392.47	(264.15)	0.05	-1.63 - 220.25
§Precordial lead STj_Tp Area in mV/ms (SD)	353.17	(215.65)	483.14	(244.65)	<0.01	-210.34 - -49.60
Baseline Type 2/3 pattern N (%)	9	(10.84%)	0	(0%)	0.02	-

449

450 **Table 5.0 Univariable analysis of statistically significant baseline ECG**

451 **characteristics between the discovery groups. §Net area**

452

	Def-BrS-Dis N=83		HC-Dis N=50		P Value	95% Confidence Interval of the Difference
	Mean	(SD)	Mean	(SD)		
QRS duration (ms)	36.27	(19.26)	26.80	(12.87)	<0.01	3.39 - 15.54
PR interval (ms)	19.45	(31.80)	42.08	(16.48)	<0.01	13.03 – 32.23
P wave duration (ms)	8.82	(25.22)	19.12	(12.50)	<0.01	-17.87 - -2.73
S wave duration lead II (ms)	26.27	(21.11)	16.36	(15.67)	<0.01	3.09 - 16.72
Anterior ST amplitude (µV)	134.99	(114.85)	26.55	(27.76)	<0.01	52.95 - 123.94
Precordial lead QRS Area (mV/ms)[§]	124.43	(297.36)	-186.80	(187.76)	<0.01	218.52 - 403.94

453

454 **Table 6.0 Univariable analysis of statistically significant Δ ECG characteristics**

455 **between the discovery groups. § Net Area**

456

	Adjusted Odds Ratio*	P Value	95% Confidence Interval
Baseline Type 2/3 Brugada Pattern	1x10 ⁹	0.999	000 - .
Baseline QRS duration (ms)	1.096	0.028	1.010 - 1.190
Baseline P wave duration (ms)	1.054	0.910	0.992 - 1.120
Baseline S wave duration lead II (ms)	0.969	0.179	0.925 - 1.015
Baseline Anterior lead ST Amplitude (uV)	1.026	0.014	1.005 - 1.046
Baseline precordial QRS area (mV/ms)[§]	1.000	0.916	0.997 – 1.003
ΔQRS duration (ms)	1.127	<0.001	1.050 – 1.209
ΔS wave duration lead II (ms)	0.967	0.232	0.916 – 1.021
ΔAnterior lead ST Amplitude (uV)	1.027	<0.001	1.012 – 1.043
ΔPrecordial lead QRS area (mV/ms)[§]	1.008	<0.001	1.004 – 1.013

457

458 **Table 7.0 Combined multivariable analysis of baseline & ΔECG characteristics**
 459 **between the discovery groups. *Per 1 unit increase in variable for quantitative**
 460 **traits. [§]Net area**

461

462 **SUPPLEMENTARY PUBLICATION MATERIAL**

463

464 **I – ONLINE QUESTIONNAIRE**

465

466 **II – INCLUSION/EXCLUSION CRITERIA**

467

468 **III – HIGH RIGHT PRECORDIAL ECG PLACEMENT**

469

470 **IV – ECG FIGURES**

471

472 **V – PAIRED ANALYSIS**

473 **REFERENCES**

474

- 475 1. Papadakis M, Papatheodorou E, Mellor G, Raju H, Bastiaenen R, Wijeyeratne Y, et
476 al. The Diagnostic Yield of Brugada Syndrome After Sudden Death With Normal Autopsy. *J*
477 *Am Coll Cardiol*. 2018;71(11):1204-14.
- 478 2. Krahn AD, Healey JS, Chauhan V, Birnie DH, Simpson CS, Champagne J, et al.
479 Systematic assessment of patients with unexplained cardiac arrest: Cardiac Arrest Survivors
480 With Preserved Ejection Fraction Registry (CASPER). *Circulation*. 2009;120(4):278-85.
- 481 3. Somani R, Krahn AD, Healey JS, Chauhan VS, Birnie DH, Champagne J, et al.
482 Procainamide infusion in the evaluation of unexplained cardiac arrest: from the Cardiac
483 Arrest Survivors with Preserved Ejection Fraction Registry (CASPER). *Heart Rhythm*.
484 2014;11(6):1047-54.
- 485 4. Hasdemir C, Payzin S, Kocabas U, Sahin H, Yildirim N, Alp A, et al. High
486 prevalence of concealed Brugada syndrome in patients with atrioventricular nodal reentrant
487 tachycardia. *Heart Rhythm*. 2015;12(7):1584-94.
- 488 5. Tadros R, Tan HL, El Mathari S, Kors JA, Postema PG, Lahrouchi N, et al. Predicting
489 cardiac electrical response to sodium-channel blockade and Brugada syndrome using
490 polygenic risk scores. *Eur Heart J*. 2019;40(37):3097-107.
- 491 6. Antzelevitch C, Yan GX, Ackerman MJ, Borggrefe M, Corrado D, Guo J, et al. J-
492 Wave syndromes expert consensus conference report: Emerging concepts and gaps in
493 knowledge. *J Arrhythm*. 2016;32(5):315-39.
- 494 7. Behr ER, Ben-Haim Y, Ackerman MJ, Krahn AD, Wilde AAM. Brugada syndrome
495 and reduced right ventricular outflow tract conduction reserve: a final common pathway? *Eur*
496 *Heart J*. 2021;42(11):1073-81.
- 497 8. Tadros R, Nannenber EA, Lieve KV, Škorić-Milosavljević D, Lahrouchi N, Lekanne
498 Deprez RH, et al. Yield and Pitfalls of Ajmaline Testing in the Evaluation of Unexplained
499 Cardiac Arrest and Sudden Unexplained Death: Single-Center Experience With 482 Families.
500 *JACC Clin Electrophysiol*. 2017;3(12):1400-8.
- 501 9. Ensam B, Cheung CC, Almeahadi F, Gregers Winkel B, Scrocco C, Brennan P, et al.
502 The Utility of Sodium Channel Provocation in Unexplained Cardiac Arrest Survivors and
503 Electrocardiographic Predictors of Ventricular Fibrillation Recurrence. *Circ Arrhythm*
504 *Electrophysiol*. 2022;15(12):e011263.
- 505 10. Peritz DC, Chung EH. Criteria for evaluating rSr' patterns due to high precordial ECG
506 lead placement accurately confirm absence of a Brugada ECG pattern. *J Electrocardiol*.
507 2016;49(2):182-6.
- 508 11. Ohkubo K, Watanabe I, Okumura Y, Ashino S, Kofune M, Nagashima K, et al. A
509 new criteria differentiating type 2 and 3 Brugada patterns from ordinary incomplete right
510 bundle branch block. *Int Heart J*. 2011;52(3):159-63.
- 511 12. Chevallier S, Forclaz A, Tenkorang J, Ahmad Y, Faouzi M, Graf D, et al. New
512 electrocardiographic criteria for discriminating between Brugada types 2 and 3 patterns and
513 incomplete right bundle branch block. *J Am Coll Cardiol*. 2011;58(22):2290-8.
- 514 13. Serra G, Baranchuk A, Bayés-De-Luna A, Brugada J, Goldwasser D, Capulzini L, et
515 al. New electrocardiographic criteria to differentiate the Type-2 Brugada pattern from
516 electrocardiogram of healthy athletes with r'-wave in leads V1/V2. *Europace*.
517 2014;16(11):1639-45.
- 518 14. Sugrue A. New electrocardiographic criteria to differentiate the type-2 Brugada
519 pattern from electrocardiogram of healthy athletes with r'-wave in leads V1/V2. *Europace*.
520 2015;17(3):504-5.
- 521